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ABSTRACT
Patients (n = 36) diagnosed with pneumococcal endophthalmitis from six Spanish hospitals between 1986
and 2004 were studied retrospectively. The diagnosis was based on clinical findings, ophthalmological
examination, and isolation of Streptococcus pneumoniae from vitreous and ⁄ or aqueous humours of 19
patients (definite diagnosis), and from other ocular specimens of 17 patients (probable diagnosis). The
mean (± SD) age was 69.3 (± 16.5) years (range 1.5–89 years), and 20 (55.5%) patients were male. The origin
of endophthalmitis was considered exogenous for 34 (94.5%) patients. The most common predisposing
factors were previous ocular surgery (n = 25, 69.4%), ocular trauma (n = 5, 13.9%), and close-to-eye
radiotherapy (n = 3, 8.3%). Eleven (30.5%) patients underwent evisceration as the first therapeutic
measure (primary evisceration), and evisceration was performed after antibiotic treatment failure
(secondary evisceration) for six (16.7%) patients. Primary evisceration was performed more commonly
(63.6%) during 1998–2004, while secondary evisceration was only performed during 1986–1997. Eighteen
(50%) patients received intra-vitreous antibiotics (mainly vancomycin), and 31 (86.1%) patients were given
systemic antibiotic therapy. The most frequent pneumococcal serogroups isolated were 6, 19, 9, 15 and 23.
Pulsed-field gel electrophoresis analysis of 23 isolates revealed that four belonged to the interna-
tional clones Spain23F-1, Spain6B-2, Spain9V-3 and Sweden15A-25. Non-susceptibility rates (i.e., interme-
diately-resistant and resistant) were: co-trimoxazole, 44.8%; penicillin, 33.3%; tetracycline, 31.0%;
erythromycin, 21.9%; chloramphenicol, 17.9%; rifampicin, 7.4%; cefotaxime, 5.9%; and levofloxacin, 0%.
Although uncommon, pneumococcal endophthalmitis is a medical emergency because of the often
aggressive clinical course, poor visual outcome and need for evisceration in a large proportion of patients.
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INTRODUCTION
Bacterial endophthalmitis is an infection invol-
ving the ocular cavity and adjacent structures
following introduction of a microorganism. It is a
serious complication of eye surgery, mainly cata-
ract removal and penetrating keratoplasty, and
ocular trauma. The incidence of endophthalmitis
following cataract removal decreased from 10%
in the 1930s to 0.3–0.07% in the 1980s [1]. The
most frequent organisms involved are coagulase-
negative staphylococci, followed by Staphylococcus
aureus and viridans group streptococci. Strepto-
coccus pneumoniae is an infrequent cause of end-
ophthalmitis, being isolated from 2.2–13.6% of
cases [2–6]. The recommended management of
bacterial endophthalmitis includes direct injection
of antibiotics into the vitreous humour [7–11],
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with vancomycin being the standard therapy for
infections caused by Gram-positive organisms,
including S. pneumoniae [7]. However, for
endogenous pneumococcal endophthalmitis, a
third-generation cephalosporin administered
intravenously, with or without intra-vitreous
administration of vancomycin, may be an appro-
priate therapeutic option.
S. pneumoniae is found rarely in normal
conjunctivae (0–0.3%) [12], but obstruction of
the nasolacrimal duct predisposes to ascendant
colonisation and infection of the lacrimal system
and conjunctivae with the normal nasopharyn-
geal commensals, including S. pneumoniae [13].
The present retrospective multicentre study
analysed 36 patients with pneumococcal end-
ophthalmitis, and formed part of a broader study
of pneumococcal disease in Spain.
MATERIALS AND METHODS
This was a retrospective study designed to evaluate the
clinical and microbiological data, treatment and outcome of
pneumococcal endophthalmitis in six Spanish hospitals
between 1986 and 2004. A protocol for data collection was
sent to all hospitals, where patients with isolates of S. pneu-
moniae from ocular samples were sought in the microbiology
records. Data were requested concerning demographics,
underlying disease, clinical data, microbiology, treatment
and outcome.
A definite case of pneumococcal endophthalmitis was
defined based on clinical findings consistent with endopht-
halmitis, such as ocular pain, progressive blurred vision,
conjunctival hyperaemia, chemosis, and lid and corneal
oedema, with isolation of S. pneumoniae from vitreous
and ⁄or aqueous humours. Probable pneumococcal endopht-
halmitis was recorded when the clinical findings were consis-
tent with endophthalmitis and S. pneumoniae was isolated
from other ocular samples, such as conjunctival exudates or
corneal scrapings. Exogenous endophthalmitis was considered
following intra-ocular surgery, ocular trauma, or sclera lacer-
ation following close-to-eye radiotherapy for face cancer.
Endogenous endophthalmitis was recorded when bacteria
were isolated from a distant anatomical site (e.g., pneumococ-
cal sepsis, meningitis) and haematogenous spread was sus-
pected.
Bacterial identification and antimicrobial susceptibility test-
ing were performed using standard methods [14]. Appropriate
antibiotic treatment included intra-vitreous vancomycin and,
for endogenous pneumococcal endophthalmitis, a parenteral
third-generation cephalosporin with or without concomitant
intra-vitreous administration of vancomycin. Serotyping and
pulsed-field gel electrophoresis (PFGE) [15] were performed
for 24 and 23 available isolates, respectively.
Statistical analysis was performed using SPSS for Win-
dows (SPSS Inc., Chicago, IL, USA); categorical variables
were analysed with chi-square or Fisher exact tests as
appropriate.
RESULTS
In total, 36 patients with pneumococcal endopht-
halmitis were diagnosed between 1986 and 2004.
Nineteen cases attended during 1986–1997, and 17
cases during 1998–2004. The mean (± SD) age was
69.3 (± 16.5) years (range 1.5–89 years), and 20
(55.5%) patients were male. There was no signi-
ficant difference in terms of which eye was
affected.
Nineteen cases were diagnosed as definite
pneumococcal endophthalmitis (Table 1), inclu-
Table 1. Clinical data for definite cases of pneumococcal endophthalmitis
Case no. (year, hospital) Age (years) Gender Previous surgery or local risk-factor Corneal ulcer Intra-vitreous therapy Systemic therapy Surgical therapy
1 (1987, HD) 86 M Cataract surgery No Gm Gm No
2 (1992, HD) 84 F Cataract surgery No No Gm, Ctx, Amc Evisceration (1st)
3 (1993, HD) 62 F Cataract surgery No No Cip, Ak Evisceration (1st)
4 (1995, FJD) 69 F Cataract surgery Yes Va No Evisceration (2nd)
5 (1996, FJD) 76 M Noa No No Cro No
6 (1996, FJD) 72 F Cataract surgery Yes Va + Ak, Pen Cip Evisceration (2nd)
7 (1996, HRC) 78 F Corneal abscess Yes Va No No
8 (1997, FJD) 88 F Cataract surgery No Va + Ak Cip Vitrectomy
9 (1999, HUB) 80 F Cataract surgery No Va + Ak Ipm + Cip No
10 (2000, HRC) 68 F Noa No Va + Ak No Vitrectomy
11 (2000, HUB) 72 F Cataract surgery No Va Ipm + Cip No
12 (2001, HRC) 63 M Glaucoma surgery No No Cip Evisceration (1st)
13 (2001, HUB) 73 F Eye trauma Yes No Ipm Evisceration (1st)
14 (2003, HRC) 76 M Cataract surgery No No No Evisceration (1st)
15 (2003, HUB) 69 M Radiotherapy Yes Va + Tm Amc, Cip No
16 (2003, HUB) 85 M Radiotherapy Yes No Ipm Evisceration (1st)
17 (2003, HUB) 77 M Cataract surgery Yes Va + Tm Cip Vitrectomy
18 (2003, HUB) 75 F Cataract surgery Yes Yes (unknown) Cip Chamber cleaning
19 (2004, HSJD) 1.5 M Glaucoma surgery No Va + Ak Va, Ctx, Cip Chamber cleaning
HD, Hospital Donostia, San Sebastia´n; FJD, Fundacio´n Jime´nez Dı´az-UTE, Madrid; HRC, Hospital Ramo´n y Cajal, Madrid; HUB, Hospital Universitari de Bellvitge, Hospitalet
de Llobregat, Barcelona; HSJD, Hospital Sant Joan de De´u, Espulgues de Llobregat, Barcelona; M, male; F, female; Ak, amikacin; Amc, amoxycillin–clavulanic acid; Cip,
ciprofloxacin; Cro, ceftriaxone; Ctx, cefotaxime; Gm, gentamicin; Ipm, imipenem; Pen, penicillin; Tm, tobramycin; Va, vancomycin; 1st and 2nd, primary and secondary
evisceration.
aCases 5 and 10 were endogenous pneumococcal endophthalmitis.
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ding 17 patients with exogenous pneumococcal
endophthalmitis and 13 with previous surgery as
a risk-factor (cataract surgery for 11 patients).
S. pneumoniae was isolated from vitreous humour
in 12 cases, from aqueous humour in four cases,
and from both in three cases. Two patients with
definite pneumococcal endophthalmitis had an
endogenous origin of infection, namely a male
aged 76 years with pansinusitis, hydrocephaly
and pneumococcal meningitis, and a female aged
68 years with diabetes mellitus type 1, kidney
carcinoma and pneumococcal septicaemia. Evis-
ceration was performed for six patients as the first
therapeutic measure (primary evisceration).
Among the remaining 13 patients, ten received
appropriate intra-vitreous antibiotic treatment,
but two required secondary evisceration. One
patient with endogenous endophthalmitis re-
ceived only parenteral ceftriaxone and no evis-
ceration was performed. One patient received an
inappropriate intra-vitreous antibiotic (gentami-
cin), and one received an unknown intra-vitreous
antibiotic; in neither case was secondary eviscer-
ation required. Fifteen patients received various
antibiotics by the systemic route. Vitrectomy was
performed for three patients, and chamber clean-
ing was performed in two cases.
Seventeen patients were diagnosed as probable
cases of pneumococcal endophthalmitis, all of
which were of exogenous origin (Table 2). In 16
cases, S. pneumoniae was isolated from conjuncti-
val exudates, and in one case from a corneal
scraping. Twelve patients had undergone previ-
ous surgery. Evisceration was performed for five
patients as a first therapeutic measure. Among the
remaining 12 patients, four received appropriate
intra-vitreous antibiotic treatment, but two re-
quired secondary evisceration. Six other patients
received parenteral rather than intra-vitreous
antibiotics, and no secondary evisceration was
required. Inappropriate intra-vitreous antibiotic
treatment (gentamicin) was administered to two
patients who underwent a secondary eviscer-
ation. Sixteen patients received various antibiotics
by the systemic route, and vitrectomy was per-
formed in one patient.
In summary, 11 (30.5%) of 36 patients were
eviscerated as the first therapeutic measure, and
six (16.7%) required secondary evisceration fol-
lowing therapeutic failure. Primary or secondary
evisceration was not related to the definite or
probable diagnosis. The risk for evisceration was
not associated statistically with the antibiotic
administered (vancomycin, third-generation cep-
halosporin, imipenem, or fluoroquinolone), and
was independent of the route of antibiotic admin-
istration, pneumococcal serogroup involved, or
antimicrobial susceptibility. Primary evisceration
was performed more often during 1998–2004
(41.2%) than during 1986–1997 (21.0%), although
the difference was not statistically significant.
Secondary evisceration was performed in four
(26.7%) of the 15 patients who received appro-
priate antibiotic treatment, and in two (22.2%) of
the nine patients who received inappropriate
intra-vitreous antibiotic treatment. Secondary
evisceration was performed in 31.6% of patients
during 1986–1997, but in none during 1998–2004
(p 0.01).
Table 2. Clinical data for probable cases of pneumococcal endophthalmitis
Case no. (year, hospital) Age (years) Gender Previous surgery or local risk-factor Corneal therapy Intra-vitreous therapy Systemic therapy Surgical
20 (1986, HD) 45 M Corneal transplantation No Gm Gm, Pen Evisceration (2nd)
21 (1991, HCA) 57 M Cataract surgery Yes No Cip + Ak + Va No
22 (1991, HD) 79 M Glaucoma surgery No No Gm + E No
23 (1991, HD) 87 M Cataract surgery Yes No Cdx, Pen, Gm Evisceration (1st)
24 (1992, HD) 76 M Glaucoma surgery Yes No Ctx Evisceration (1st)
25 (1992, HCA) 89 F Eye trauma Yes No Amp + Gm, Cfr No
26 (1993, FJD) 58 M Radiotherapy No Va + Gm Va + Ak, Pen Evisceration (2nd)
27 (1995, FJD) 48 F Corneal transplantation No Va + Ak Ak No
28 (1996, HD) 79 M Cataract surgery No Gm Va, Cip, Caz Evisceration (2nd)
29 (1997, HD) 47 M Eye trauma No Va Caz, Pen, Amc, Va, Rif Evisceration (2nd)
30 (2000, HD) 80 M Cataract surgery No No Caz + Va Evisceration (1st)
31 (2000, HRC) 57 F Cataract surgery Yes No Va + Ak Evisceration (1st)
32 (2000, HD) 72 M Cataract surgery No No Caz + Va Vitrectomy
33 (2003, HD) 78 F Eye trauma Yes No Caz + Va, Cip Evisceration (1st)
34 (2003, HD) 71 M Cataract surgery No Va + Caz No No
35 (1994, HD) 61 M Eye trauma Yes No Amc, Cip Keratoplasty
36 (2004, HCA) 56 F Corneal transplantation Yes No Caz + Va, Lvx No
HCA, Hospital Central de Asturias, Oviedo; FJD, Fundacio´n Jime´nez Dı´az-UTE, Madrid; HRC, Hospital Ramo´n y Cajal, Madrid; M, male; F, female; Ak, amikacin; Amc,
amoxycillin–clavulanic acid; Caz, ceftazidime; Cdx, cefadroxil; Cfr, cephaloridine; Cip, ciprofloxacin; Ctx, cefotaxime; E, erythromycin; Gm, gentamicin; Lvx, levofloxacin; Pen,
penicillin; Rif, rifampicin; Va, vancomycin; 1st and 2nd, primary and secondary evisceration.
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Microbiological data are shown in Table 3.
Twenty-four isolates were serotyped; 15 different
pneumococcal serogroups were detected, but
58.3% of isolates belonged to five serogroups.
The most frequent serogroups were 6 and 19,
followed by 9, 15 and 23.
Isolates were non-susceptible to penicillin in 12
(33.3%) cases, to cefotaxime in two (5.9%), to
erythromycin in seven (21.9%), to rifampicin in
two (7.4%), to chloramphenicol in five (17.9%), to
tetracycline in nine (31.0%), and to co-trimoxazole
in 13 (44.8%). The percentages of penicillin-non-
sensitive isolates during the two periods were
similar (58.3% and 54.5% during 1986–1997 and
1998–2004, respectively). All the isolates tested
were susceptible to levofloxacin.
Although 23 different PFGE patterns were
observed, those of the isolates from four patients
were indistinguishable from the PFGE patterns of
the major antimicrobial-resistant clones defined
previously (The Pneumococcal Molecular Epi-
demiology Network: http://www.sph.emory.edu/
PMEN/index.html), i.e., Spain23F-1 (patient 1),
Sweden15A-25 (patient 11), Spain6B-2 (patient 22)
and Spain9V-3 (patient 34).
DISCUSSION
Pneumococcal endophthalmitis is an uncommon
eye infection, but is associated with a more
aggressive clinical course and poorer visual out-
come [4,6,16] than endophthalmitis caused by
coagulase-negative staphylococci or Propionibac-
terium spp. [17–20]. The disease occurs mainly in
the elderly because it is often associated with
surgical procedures performed commonly in this
age group [7]. In the present study, all but one
patient (aged 18 months with congenital glau-
coma who underwent goniotomy) were aged
> 44 years. Most (94.4%) cases of endophthalmitis
were considered to be of exogenous origin, as
has been reported previously [7,16]. Cataract
and glaucoma surgery, eye trauma, close-to-eye
radiotherapy and corneal transplant were the
conditions associated most frequently with
pneumococcal endophthalmitis in the present
Table 3. Microbiological characteristics of 36 bacterial isolates from cases of pneumococcal endophthalmitis
Case no. Serogroup ⁄ serotype Sample Pen Ctx E Lvx Sxt Tet C Rif PFGE patterna
1 23F A, C R S S S R R R S Spain23F-1
2 20 V S S S S S S S S A
3 17 V S S S S R R S S B
4 – V S S S – S – – – –
5 – A, V R – S – – – – – –
6 – A, V S S – – S – – – –
7 – V S S S – – S S S –
8 – A, V R – R – S – – – –
9 18C A S S S S S S S S C
10 – V S S S – – S S S –
11 15A V I S R S S R S S Sweden15A-25
12 – A S S R – R R – – –
13 19 V R S R S R R R S D
14 – V S S – – – – – – –
15 4 V S S S S S S S S E
16 19A V I S R S S R S S F
17 35 V S S S S S S S S G
18 6A V S S R S S S S S H
19 – A S S R – R – – – –
20 19 C I S S S I S S S –
21 19 C S S S S S S S S I
22 6B C R I S S I R R S Spain6B-2
23 28 C S S S S S S S S J
24 13 C S S S S S S S S K
25 23 C I S S S I R R S L
26 – C S S S – – S S – –
27 – C I S – – – R R S –
28 8 C S S S S S S S S M
29 3 C S S S S S S S S N
30 9V C I S S S S S S S O
31 – CS I I – – – – – – –
32 6 C S S S S I S S S P
33 15 C S S S S R S S R Q
34 9V C R S S S R S S S Spain9V-3
35 6 C S S S S R S S R R
36 34 C S S S S R S S S S
A, aqueous humour; C, conjunctival; CS, corneal scraping; V, vitreous humour; PFGE, pulsed-field gel electrophoresis; C, chloramphenicol; Ctx, cefotaxime; E, erythromycin;
Lvx, levofloxacin; Pen, penicillin; Rif, rifampicin; Sxt, co-trimoxazole; Tet, tetracycline; I, intermediately-resistant; R, resistant; S, susceptible.
aDesignations A–S in this column refer to different PFGE patterns.
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series. Three cases of pneumococcal endophthalm-
itis were detected in patients who underwent
corneal transplantation. These infections may be
associated with the surgical procedure, but have
been also related in previous studies to colonisa-
tion of the donor’s cornea by streptococci and
other organisms [21–23]. As most cases of end-
ophthalmitis are complications following eye sur-
gery, preventive measures such as pre-surgical
application of povidone-iodine solution to the skin
and conjunctiva, meticulous draping of the eyes, a
careful surgical technique and post-operative
injection of sub-conjunctival antibiotics have been
recommended [24,25]. Endogenous pneumococcal
endophthalmitis is a very rare complication, with
only c. 20 cases reported since 1960, including two
cases from the present study [7,26–37].
The serogroups isolated in the present series
did not differ from those involved in other
pneumococcal infections, with 83.3% covered by
the 23-valent polysaccharide vaccine, although
the possible impact of immunisation on the
incidence of pneumococcal endophthalmitis is
not known.
No genetic relatedness was found among 23 of
36 isolates that were characterised by PFGE. The
multiresistant clones Spain23F-1, Sweden15A-25,
Spain6B-2 and Spain9V-3 comprised 30.8% (4 ⁄ 13)
of all penicillin-non-susceptible isolates. Although
these four international clones are disseminated
widely in Spain, no clusters of cases involving
these clones were observed.
Unfortunately, the retrospective nature of the
present study, as well as the diversity of contri-
buting hospitals, meant that complete data were
not available for all cases, including the delay
between surgery and disease onset, the time
between disease onset and antibiotic treatment,
adjuvant therapy with steroids, and visual out-
come of conserved eyes.
When endophthalmitis is suspected, the patho-
gen is typically unknown and the antimicrobial
regimen is chosen empirically. The recommended
management of bacterial endophthalmitis in-
cludes direct injection of antibiotics into the
vitreous humour [7–11]. The antibiotics used
most commonly for intra-vitreal administration
are vancomycin, amikacin and ceftazidime, but
only vancomycin is active uniformly against
S. pneumoniae. Although fluoroquinolones are
usually active against S. pneumoniae, there is
concern about potential toxicity if fluoroquinolo-
nes are injected directly into the vitreous humour
[38,39]. A few reports in humans and animals
have suggested that clarithromycin and imipe-
nem could also be administered by the intra-
vitreous route [40,41]. Sub-conjunctival injections
of antibiotics have also been recommended, but
the intra-vitreous concentrations of vancomycin,
ceftriaxone and ceftazidime achieved after sub-
conjunctival administration have been extremely
low when these agents have been administered as
prophylaxis before vitrectomy [42]. Sub-conjunc-
tival cefotaxime has been given to patients sched-
uled to undergo elective vitreal surgery, but
therapeutic levels in the vitreous humour were
found only in patients with aphakia or in those
who had undergone vitreal surgery previously
[43].
Systemic antibiotics have also been used con-
currently for treatment of bacterial endophthalm-
itis [33,44]. Vancomycin given intravenously does
not achieve significant vitreous concentrations in
patients with post-surgical endophthalmitis [45],
although concentrations well above the MICs for
many Gram-positive pathogens were obtained in
a rabbit model [46]. Ceftazidime penetrates into
the vitreous cavity of inflamed eyes, mainly
aphakic, vitrectomised eyes [47], but this antibi-
otic has poorer anti-pneumococcal activity than
cefotaxime and ceftriaxone [48,49]. Penetration
into the vitreous humour after intramuscular
administration of equivalent doses of both cefo-
taxime and ceftriaxone is higher for the latter
cephalosporin [43,50]. Imipenem penetrates the
inflamed and non-inflamed vitreous humour
better than other antibiotics [51,52]. The good
penetration and the low rate of resistance in
pneumococci make imipenem a good option for
parenteral treatment. Although ciprofloxacin pen-
etrates the inflamed and non-inflamed vitreous
humour [53], other fluoroquinolones with greater
activity against S. pneumoniae, such as moxifloxa-
cin and gatifloxacin, achieve therapeutic levels in
the non-inflamed human eye [54,55]. In uninfect-
ed rabbits treated with a single dose of rifampicin,
concentrations above the MIC have been achieved
for many organisms, including S. pneumoniae, in
the aqueous and vitreous humours, but there is
no clinical experience with rifampicin for the
treatment of bacterial endophthalmitis [56]. Des-
pite all these data, the systemic use of antibiotics
for the treatment of bacterial endophthalmitis is
not well-standardised, and the Endophthalmitis
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Vitrectomy Study concluded that the use of
systemic antibiotics in combination with intra-
vitreal administration did not improve the final
visual acuity or media clarity [10].
Although an ocular inflammatory response is
vital for the clearance of organisms during an
infection, such a response can cause damage to
neurological tissues. The use of intra-vitreous
corticosteroids for treatment of bacterial endopht-
halmitis is controversial, but its beneficial effect
has been shown in an experimental model of
pneumococcal endophthalmitis [57], although
most clinical studies have shown either no effect
[58–60] or a detrimental effect in experimental
Staph. aureus endophthalmitis [61]. Despite the
conflicting results, intra-vitreous administration
of dexamethasone and antibiotics is used fre-
quently for therapy of endophthalmitis.
Vitrectomy is performed frequently to cure
bacterial endophthalmitis, but routine immediate
pars plana vitrectomy seems to be unnecessary
for patients with better than light perception
vision at presentation. However, a substantial
benefit has been observed for those patients who
have light perception only vision [10].
In 17 (47.2%) of the present cases, evisceration
of the affected eye had to be performed, with this
procedure being a first therapeutic measure in 11
(30.5%) cases, and being performed in the
remaining cases after verification of antibiotic
treatment failure. These data show a trend for
more aggressive surgical treatment (primary evis-
ceration) during 1998–2004 compared with 1986–
1997. In contrast, secondary evisceration was only
performed during 1986–1997, a difference that
was statistically significant. These results seem to
be related to different medical approaches, with
more aggressive medical practice occurring in
recent years. Furthermore, secondary evisceration
was not related to the appropriateness of intra-
vitreous antibiotic treatment.
In conclusion, pneumococcal endophthalmitis,
although rare, is a medical emergency, often with
an acute onset and an aggressive clinical course.
Poor visual outcome, and even evisceration, are
common in this devastating disease.
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